EVIDENCE SYNTHESIS FOR GLOBAL HEALTH: ANIMAL STUDIES UNDER THE LENS
|
|
- Walter Martin
- 5 years ago
- Views:
Transcription
1 EVIDENCE SYNTHESIS FOR GLOBAL HEALTH: ANIMAL STUDIES UNDER THE LENS Paul Garner On behalf of the Cochrane infectious Diseases Group Editors And the Effective Health Care Research Programme Consortium
2 Competing interests Funded by the UK Aid Programme to increase the number of decisions based on reliable evidence in health for the poor in developing countries
3
4
5 previously UK Aid policies were well meaning, but based on expert opinion Example from the British Colonial Service for the Punjab
6
7
8
9
10 1993
11 Systematic reviews 1. Responses from our stakeholders over 20 yr. 2. Findings from a ASR of a new TB vaccine 3. Personal reflections on the agenda
12 Funders Synthesis Researchers Policy maker
13 Stakeholders Our funders
14 Research governance framework for health and social care (2001)
15
16 Global policy makers guidelines panels/advocates Category 1. Those that are happy
17 Amodiaquine (Lancet 1996) 50 studies Better than chloroquine WH O reintroduced in Africa 1998 Impregnated mosquito nets for malaria (Cochrane 1997) Low osmolarity ORS (BMJ/Cochrane 2001) 14 studies Reduced child mortality Helped underpin investment studies Better Changed formula 2003 Artemisinin combination Rx (Lancet 2004) 30 studies 70% increase in cure ACTs first line 2007 Artesunate severe malaria (Cochrane 2007) 8 studies 40% fewer deaths WHO rec 2008
18 Global policy makers guidelines panels/advocates Category 2. Those that are cross
19 Direct observation for TB (BMJ/Cochrane 1997) Deworming for schoolchildren (Cochrane 1996/2011) Primaquine single dose to block transmission (Cochrane 2012/4) 5 studies No difference Controversy Modified early studies Exaggerated claims Investment continued until recently 15 studies Inadequate data Policy remains; research continues
20 Belief disconfirmation bias Belief-confirming evidence: Belief-disconfirming evidence: taken at face value intense critical evaluation
21 Belief disconfirmation bias Standard responses: Original research methods is flawed Synthesis cannot be used here Data incomplete-studies missed You have applied the methods wrongly Synthesis authors are uninformed/ incompetent/trouble makers
22 Cochrane review Does routine deworming improve children s health, performance at school and contribute to economic development?
23
24
25
26
27
28 Deworming review: accountability in question One trial of 22,000 children in 60 clusters showed increased weight gain because it did not adjust for clustering A trial from Vietnam of over 300 children that looked at school performance has never been published One trial of 2 million children remained unpublished 6 years after recruitment ended Re-analysis of Miguel and Kremer study (Nov 2014) the claimed externality effects vanished & no effect on nutrition Plus one more
29 Increasingly Academic competing interests causes substantive biases and distortion Academic behaviour often challenges the principles of scientific integrity
30
31 Systematic review of prime boost TB vaccine Rufaro Kashangura, Emily S. Sena, Taryn Young, Paul Garner
32 Protocol driven study Comparison: vaccine + BCG vs. BCG Animals: any Design: TB challenge given Outcomes: Mortality/euthanasia, pathology in lungs, and bacterial loads in lung
33 Methods Comprehensive search Double application of inclusion criteria Study quality assessed Cumulative meta-analysis
34
35 quality
36 Criteria Were sample size and power calculations given? Was the number of animals clear? Was competing interest declared? Was there randomisation? Was there baseline comparability? Was the outcome assessor blind? Humane endpoint Pathology Bacteriol Williams Williams Goonetille Romano Tchilian Verrick Vorderme Sharpe 2005 (a) 2005 (b) ke ier No No No No No No No No Yes Yes No Yes No Yes Yes Yes No COI statement Not reported All g female pigs Not reported Not reported but objective Not reported No COI statement Not reported Same species pigs Not reported No COI statement Not reported All 8-10wk old female mice. Not reported No COI statement Not reported All 8-10 weeks old mice. Not reported No COI statement Not reported All 6-8wk old female mice. Not reported Contains COI with conflict Yes Same age weight, male macaques. Not reported Contains COI with conflict Not Reported All six month old cattle. No COI statemen t Not reported All 4 yr old macaque s. Not reported Yes Yes Only lesion volume blinded Not reported Not reported Not reported
37 Outcomes
38 Bacterial load
39 Pathology summary Authors conclusion Our interpretation William 2005 Guinea pigs Not able to discriminate No data provided (b) 14 William 2005 (b) 14 Guinea pigs Not significantly better than BCG No data provided Verrick 2009 c 18 Macaques BCG/MVA85A less severe disease and fewer lesions than BCG only Vordermeier Calves Sharpe Macaques significantly reduced after MVA85A vaccination compared to control f No statistical difference between MVA85A vaccinated and BCG vaccinated animals for lesions in lung, lung pathology and gross pathology scoring Scores in both BCG alone and MVA85A boost much lower than controls No direct statistical comparison between MVA85A and BCG. No statistical difference but more lesions in BCG and MVA85A groups. Other parameters show no trends
40 Mortality
41
42 Implications for strategy We as a group have a duty to develop the science and reviews in this area It has to be independent of the researchers The so called scientists will be sceptical (watch for belief disconfirmation bias ) We have to get FUNDERS and the PUBLIC onside
Global progress in vaccine development
Global progress in vaccine development Helen McShane The Jenner Institute University of Oxford helen.mcshane@ndm.ox.ac.uk Vaccination The most cost-effective health intervention Smallpox Poliomyelitis
More informationVector control and policy: systematic reviews
Vector control and policy: systematic reviews Funding source I am funded by UKAid to increase decisions based on reliable evidence in health in LMIC I am responsible for the WHO Collaborating Centre for
More informationInstrument for the assessment of systematic reviews and meta-analysis
Appendix II Annex II Instruments for the assessment of evidence As detailed in the main body of the methodological appendix (Appendix II, "Description of the methodology utilised for the collection, assessment
More informationCan we afford DAA for all???
The 4P Group Public Health Community Physicians and scientists Policy makers Pharmaceutical companies Can we afford DAA for all??? Maud Lemoine Imperial College London MRC, the Gambia Unit, West Africa
More informationEstimating TB burden. Philippe Glaziou World Health Organization Accra, Ghana
Estimating TB burden Philippe Glaziou World Health Organization Accra, Ghana Outline Basic facts about TB epidemiology What should we expect with regards TB burden over time? Main indicators of TB disease
More informationUpdate on TB Vaccines
Update on TB Vaccines Hennie Geldenhuys 11 May 2012 A safe and effective TB Vaccine within a decade A Strategic Blueprint for the Next Decade Tuberculosis, Vol 92, March 2012, Suppl. 1, pgs S1-S35 On
More informationUNICEF AND MALARIA MEDICINES. Supply Division October 2006
UNICEF AND MALARIA MEDICINES Supply Division October 2006 PROCUREMENT SERVICES SUPPORTING CHILD RIGHTS UNICEF PROVIDES PROCUREMENT SERVICES AS PART OF ITS MANDATE Helping partners access resources for
More informationAlcohol interventions in secondary and further education
National Institute for Health and Care Excellence Guideline version (Draft for Consultation) Alcohol interventions in secondary and further education NICE guideline: methods NICE guideline Methods
More informationHow to optimise immunisation: a live vaccine last policy. Frank Shann University of Melbourne
How to optimise immunisation: a live vaccine last policy Frank Shann University of Melbourne We can no longer assume that a vaccine: 1. Acts independently of other vaccines 2. Influences only infections
More informationAnalysis of the demand for a malaria vaccine: outcome of a consultative study in eight countries
Briefing Document: National decision-making framework for malaria vaccines Analysis of the demand for a malaria vaccine: outcome of a consultative study in eight countries This is one of seven briefing
More informationRARE-Bestpractices Conference
RARE-Bestpractices Conference 24 November 2016, Istituto Superiore di Sanità, Rome, Italy Avoiding waste in production, design and conduct of studies and reporting evidence on rare diseases Philippe Ravaud
More informationCritical Thinking A tour through the science of neuroscience
Critical Thinking A tour through the science of neuroscience NEBM 10032/5 Publication Bias Emily S Sena Centre for Clinical Brain Sciences, University of Edinburgh slides at @CAMARADES_ Bias Biases in
More informationChemoprophylaxis and intermittent treatment for preventing malaria in children (Review)
Chemoprophylaxis and intermittent treatment for preventing malaria in children (Review) Meremikwu MM, Donegan S, Esu E This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration
More informationThe human immunodeficiency virus/acquired immune
Vol. 7(4), pp. 44-48, May 2015 DOI: 10.5897/JAHR2014.0320 Article Number: 70F676253212 ISSN 2141-2359 Copyright 2015 Author(s) retain the copyright of this article http://www.academicjournals.org/jahr
More informationGRADE tables to assist guideline development and recommendations. Plain Language Summary of Results
Seasonal Malaria Chemoprevention (formally known as Intermittent Preventive Treatment in children) for preventing malaria morbidity in children aged less than 5 years living in areas of marked seasonal
More informationCopenhagen, Denmark, September August Malaria
Regional Committee for Europe 64th session EUR/RC64/Inf.Doc./5 Copenhagen, Denmark, 15 18 September 2014 21 August 2014 140602 Provisional agenda item 3 ORIGINAL: ENGLISH Malaria Following the support
More informationAgainst intervention No recommendation Strong Conditional Conditional Strong. For intervention. High Moderate Low Very low
Draft recommendation: Consider using MDA as an additional tool for the elimination of malaria in low prevalence island or nonisland settings where the risk of imported malaria is low Balance of desirable
More informationWhy published medical research may not be good for your health
Why published medical research may not be good for your health Doug Altman EQUATOR Network and Centre for Statistics in Medicine University of Oxford 2 Reliable evidence Clinical practice and public health
More informationWG: Vaccinations and child survival Focus:
WG: Vaccinations and child survival Focus: Monitoring childhood interventions including routine services and campaigns => To find possible changes in policy Why is that necessary? Paradox: All interventions
More informationAntimicrobial resistance Fact sheet N 194 Updated April 2014
Antimicrobial resistance Fact sheet N 194 Updated April 2014 Key facts Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by
More informationTB Vaccine Research and Development: Progress, Strategies and Controversies
15 March 2016 GVIRF Global Forum Johannesburg, South Africa TB Vaccine Research and Development: Progress, Strategies and Controversies Lewis Schrager, M.D. V.P., Scientific Affairs Rockville, MD USA Source:
More informationMalaria. Edwin J. Asturias, MD
Malaria Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health, Colorado School of Public Health Global Health and Disasters Course
More informationBehaviour Change: Supporting interventions for introduction of malaria RDTs in Cameroon & Nigeria
Behaviour Change: Supporting interventions for introduction of malaria RDTs in Cameroon & Nigeria ACT Consortium LSHTM: Virginia Wiseman, Lindsay Mangham-Jefferies, Bonnie Cundill, Clare Chandler, Neal
More information38 Current Concepts in
38 Current Concepts in Management of Falciparum Malaria Abstract: Artemisinin based Combination Therapy (ACT) is the preferred agent to treat drug resistance uncomplicated Plasmodium Falciparum (PF) Malaria.
More informationCEU screening programme: Overview of common errors & good practice in Cochrane intervention reviews
CEU screening programme: Overview of common errors & good practice in Cochrane intervention reviews Since September 2013, the CEU has been responsible for pre-publication screening of new intervention
More informationTHE Price of a Pandemic 2017
THE Price of a Pandemic 2017 From 2000-2015: 33 million people died because of TB at a global economic cost of $617bn This report was produced the Global TB Caucus, an international network of over 2,000
More informationSchool of Dentistry. What is a systematic review?
School of Dentistry What is a systematic review? Screen Shot 2012-12-12 at 09.38.42 Where do I find the best evidence? The Literature Information overload 2 million articles published a year 20,000 biomedical
More information#4 (Tuberculosis OR TB OR Pulmonary Tuberculosis OR Multi-Drug Resistant Tuberculosis OR MDR OR Extremely-Drug Resistant Tuberculosis or XDR)
DATABASE Cochrane Database of Systematic Reviews DATE 15 DECEMBER 2015 #1 Safety of Crucell Ad35/ AERAS-402 OR Effectiveness of Crucell Ad35/ Aeras-402 OR Safety of MVA85A/ Aeras-485 OR Effectiveness of
More informationSPECIAL EVENT ON PHILANTHROPY AND THE GLOBAL PUBLIC HEALTH AGENDA. 23 February 2009, United Nations, New York Conference Room 2, 3:00 p.m. 6:00 p.m.
SPECIAL EVENT ON PHILANTHROPY AND THE GLOBAL PUBLIC HEALTH AGENDA 23 February 2009, United Nations, New York Conference Room 2, 3:00 p.m. 6:00 p.m. ISSUES NOTE Improving the Health Outcomes of Women and
More informationGambling attitudes and misconceptions
FINDINGS The results have been presented showing the effect sizes of interventions. When heterogeneity was absent the studies were pooled. However, the confidence intervals should be considered with caution.
More informationAntimalarials in the WHO Essential Drugs List for Children Reviewer No.1
Antimalarials in the WHO Essential Drugs List for Children Reviewer No.1 Part I: Evaluation of the current list Proposed grouping from the March 2007 meeting 6.5.3 Antimalarial medicines 6.5.3.1 For curative
More informationImproving Return on Public Health Investments in Disasters with Evidence Synthesis
Improving Return on Public Health Investments in Disasters with Evidence Synthesis Karen A. Robinson Johns Hopkins University Evidence Aid 17 Nov 2016 Evidence Synthesis Formal methods for summarizing
More informationDisclosure Information
Malaria Medications Charlie Mosler, RPh, PharmD, CGP, FASCP Assistant Professor of Pharmacy Practice The University of Findlay College of Pharmacy Findlay, OH mosler@findlay.edu Disclosure Information
More informationImplementing the Abuja Declaration and Plan of Action: the journey so far
Implementing the Abuja Declaration and Plan of Action: the journey so far The Abuja Declaration African leaders who met on 25 April 2000 in Abuja, Nigeria, laid out the foundation for a sustained battle
More informationThe potential public health impact of new TB vaccines
The potential public health impact of new TB vaccines 5 th Global Forum on TB Vaccines Richard White 1,2, Rebecca Harris 2, Chathika Weerasuriya 2 1 TB Modelling and Analysis Consortium 2 TB Modelling
More informationA New Class of Malaria Drugs: The Coartem Breakthrough from Novartis
A New Class of Malaria Drugs: The Coartem Breakthrough from Novartis and its Chinese Partners Hans Rietveld, Director, Global Access and Marketing, Malaria Initiative, Novartis Pharma AG Workshop on Access
More informationHOW EFFECTIVE ARE ANTIVIRAL DRUGS AGAINST INFLUENZA? Dr Puja Myles
HOW EFFECTIVE ARE ANTIVIRAL DRUGS AGAINST INFLUENZA? Dr Puja Myles Puja.myles@nottingham.ac.uk ANTIVIRALS CURRENTLY USED IN INFLUENZA Previously, M2-inhibitors (amantadine and rimantadine) From 1999, Neuraminidase
More informationFactors affecting child development in developing countries
Factors affecting child development in developing countries S Grantham-McGregor Centre for Health and Development, Institute of Child Health, University College London Figure 1.1 The Lancet series: The
More informationAccelerating progress towards the health-related Millennium Development Goals
Accelerating progress towards the health-related Millennium Development Goals The critical role of the national health policy & strategy in strengthening health systems and delivering effective interventions
More informationThe DIABETES CHALLENGE IN PAKISTAN FIFTH NATIONAL ACTION PLAN
1. INTRODUCTION The DIABETES CHALLENGE IN PAKISTAN FIFTH NATIONAL ACTION PLAN 2014 2018 UNITE AGAINST DIABETES STOP RISING TREND Diabetes is a significant and growing challenge globally that affects individuals,
More informationGlobal health and vaccination: TB & beyond. Dr Mary Moran Executive Director
Global health and vaccination: TB & beyond Dr Mary Moran Executive Director mmoran@policycures.org Outline About Policy Cures 3 reasons to focus on vaccine innovation Where are we today? The pipeline Where
More informationNovartis: tackling adherence. ESPACOMP, September, 2010
Novartis: tackling adherence ESPACOMP, September, 2010 Novartis is a world-leading healthcare company Leading market position One of 20 largest companies by market capitalization Among most respected companies
More informationCrude health statistics
Crude health statistics Crude health stats are measurements of indicators that come directly from primary data collection with no adjustment or corrections Drawbacks Incomplete ascertainment Non representativeness
More informationART for prevention the task ahead
ART for prevention the task ahead Dr Teguest Guerma WHO/HQS WHO's role and vision Status of the epidemic Overview Progress and challenges in treatment and prevention scale up ART for prevention Questions
More informationTB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director
TB 2015 burden, challenges, response Dr Mario RAVIGLIONE Director Addis Ababa, Ethiopia 11-13 November 2015 Overview TB basics TB burden & challenges Response: End TB Strategy DAY 1 What is TB? Definition
More informationTanzania s Progress in Combating Malaria: Achievement and Challenges
Tanzania s Progress in Combating Malaria: Achievement and Challenges DR RENATA A MANDIKE DEPUTY PROGRAMME MANAGER NATIONAL MALARIA CONTROL PROGRAMME, MINISTRY OF HEALTH, COMMUNITY DEVELOPMENT, GENDER,
More informationJournal Assignment #2. Malaria Epidemics throughout the World
Journal Assignment #2 Malaria Epidemics throughout the World In this assignment, you will study malaria and how it has impacted several world regions and how its global impact has had devastating effects
More informationIf I m interested, why is it a conflict? Ross McKinney, Jr, MD
If I m interested, why is it a conflict? Ross McKinney, Jr, MD Overview Define Conflicts of Interest Consider the effects of COI on research Propose that bias and non-reproducibility are larger problems
More informationCombination Anti-malarial Therapy and WHO Recommendations
Prakaykaew Charunwatthana 2, and Sasithon Pukrittayakamee 1,2 1 Associate Fellow of the Royal Institute, Academy of Science 2 Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol
More informationDeveloping Logic Models
Developing Logic Models Developing Logic Models 2 An introduction to using Logic Models in CIDG reviews. What are Logic Models? Logic models are diagrams which map out important concepts within a systematic
More informationMonitoring tuberculosis progression using MRI and stereology
Monitoring tuberculosis progression using MRI and stereology TB the problem Estimated number of new cases in 2007 2 million deaths; 9 million new cases p.a. TB kills someone every 15 secs, 9,153 cases
More informationDEVELOPMENT. The European Union confronts HIV/AIDS, malaria and tuberculosis. A comprehensive strategy for the new millennium EUROPEAN COMMISSION
DEVELOPMENT The European Union confronts HIV/AIDS, malaria and tuberculosis A comprehensive strategy for the new millennium EUROPEAN COMMISSION DE 121 FEB 2004 A global challenge Every minute, 11 people
More informationSuraj Madoori, Treatment Action Group, U.S. and Global Health Policy Director. On behalf of the Tuberculosis Roundtable
United States House of Representatives Committee on Appropriations Subcommittee on State and Foreign Operations and Related Programs Fiscal Year 2020 Written Testimony Suraj Madoori, Treatment Action Group,
More informationMonitoring of the achievement of the health-related Millennium Development Goals
SIXTY-THIRD WORLD HEALTH ASSEMBLY WHA63.15 Agenda item 11.4 21 May 2010 Monitoring of the achievement of the health-related Millennium Development Goals The Sixty-third World Health Assembly, Having considered
More informationWashington, DC, November 9, 2009 Institute of Medicine
Holger Schünemann, MD, PhD Chair, Department of Clinical Epidemiology & Biostatistics Michael Gent Chair in Healthcare Research McMaster University, Hamilton, Canada Washington, DC, November 9, 2009 Institute
More informationRATING OF A RESEARCH PAPER. By: Neti Juniarti, S.Kp., M.Kes., MNurs
RATING OF A RESEARCH PAPER RANDOMISED CONTROLLED TRIAL TO COMPARE SURGICAL STABILISATION OF THE LUMBAR SPINE WITH AN INTENSIVE REHABILITATION PROGRAMME FOR PATIENTS WITH CHRONIC LOW BACK PAIN: THE MRC
More informationFunding Opportunities for Public Health Research
Funding Opportunities for Public Health Research IPH Open Conference,Titanic Belfast, 11 October 2016 Dr Nicola Armstrong Programme Manager HSC R&D Division, Public Health Agency Outline Strategic Context
More informationCopyright GRADE ING THE QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS NANCY SANTESSO, RD, PHD
GRADE ING THE QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS NANCY SANTESSO, RD, PHD ASSISTANT PROFESSOR DEPARTMENT OF CLINICAL EPIDEMIOLOGY AND BIOSTATISTICS, MCMASTER UNIVERSITY Nancy Santesso,
More informationWhat is new. Sandra Caldeira, Joint Research Centre
What is new Joint Meeting of the High Level Group on Nutrition and Physical Activity and the EU Platform for Action on Diet, Physical Activity and Health Brussels, 10 June 2014 Sandra Caldeira, Joint Research
More informationRoss Fund Summary January 2016
Ross Fund Summary January 2016 Ross Fund The 1 billion Ross Fund was announced by the Chancellor of the Exchequer in November 2015 and will be managed by Department for International Development (DFID)
More informationUnderstanding vaccine development
Understanding vaccine development Firdausi Qadri Director, Centre for Vaccine Sciences International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) Outline of this talk 1. Understanding disease
More informationUpdate on TB Vaccines. Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town
Update on TB Vaccines Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town 1 Robert Koch s Therapeutic TB vaccine 1890: Purified Tuberculin Protein 1891: First negative reports
More informationEQUATOR Network: promises and results of reporting guidelines
EQUATOR Network: promises and results of reporting guidelines Doug Altman The EQUATOR Network Centre for Statistics in Medicine, Oxford, UK Key principles of research publications A published research
More informationHuman Health Using nuclear techniques to improve health around the world
Human Health Using nuclear techniques to improve health around the world With its wide range of activities and expertise in nuclear science and medicine, the IAEA is helping Member States use nuclear techniques
More informationHIV-1 Vaccine Development Clinical Trials and Public Health Benefits Chaiyos Kunanusont HIV/AIDS Adviser United Nations Population Fund
The 2 nd Advanced Vaccinology course (NVCO) DDC, Radisson Bangkok 15 17 June 2010 HIV-1 Vaccine Development Clinical Trials and Public Health Benefits Chaiyos Kunanusont HIV/AIDS Adviser United Nations
More informationThe Johns Hopkins Vaccine Initiative Johns Hopkins Bloomberg School of Public Health
WHO Internships (Terms of Reference) for VIEW Scholars Program January 2010 A. Examining approaches to collecting and analyzing HPV vaccine coverage data B. County level burden of disease estimates for
More informationCancer research investment should shift from late stage treatment to early stage detection No!
Cancer research investment should shift from late stage treatment to early stage detection No! KC Soo National Cancer Centre Singapore Duke-NUS Graduate Medical School 3 caveats 1. The primacy of cancer
More informationEnding Malaria in Nigeria: The WHO Agenda
Nigeria Institute of Medical Research 2016 World Malaria Day Lecture 27 April, 2016 Ending Malaria in Nigeria: The WHO Agenda Dr Tolu Arowolo Malaria Containment Programme, WHO, Nigeria arowolot@who.int
More informationThe non-human primate model in TB vaccine development
April 10, 2015 The non-human primate model in TB vaccine development Tom Evans MD Aeras Agenda Issues Transmission studies Recent advancements Outcomes Endpoint analysis Design Going forward 2 Development
More informationVersion for the Silent Procedure 29 April Agenda item January Hepatitis
Version for the Silent Procedure 29 April 2014 134th session EB134.R18 Agenda item 10.5 25 January 2014 Hepatitis The Executive Board, Having considered the report on hepatitis, 1 RECOMMENDS to the Sixty-seventh
More informationUSDA Nutrition Evidence Library: Systematic Review Methodology
USDA Nutrition Evidence Library: Systematic Review Methodology Julie E. Obbagy, PhD, RD USDA Center for Nutrition Policy & Promotion Meeting #2 October 17, 2016 The National Academies of Sciences, Engineering,
More informationThe growing burden of noncommunicable diseases (NCDs)
The WHO Noncommunicable Diseases Global Surveillance Strategy: Experience in the African Region Burden of noncommunicable diseases The growing burden of noncommunicable diseases (NCDs) represents a major
More informationMathematical modelling to accelerate development of new tuberculosis vaccines
Mathematical modelling to accelerate development of new tuberculosis vaccines Preliminary Results Rebecca Harris, Tom Sumner, Gwen Knight and Richard White 22 nd February 2018 Harris et al. 2016 Modelling
More informationOverview of the Malaria Vaccine Implementation Programme (MVIP) Prof. Fred Were SAGE meeting 17 April, 2018
Overview of the Malaria Vaccine Implementation Programme (MVIP) Prof. Fred Were SAGE meeting 17 April, 2018 1 Objectives Brief review Background EMA positive opinion and WHO recommendations Funding Description
More informationDetermining the size of a vaccine trial
17th Advanced Vaccinology Course Annecy 26 th May 2016 Determining the size of a vaccine trial Peter Smith London School of Hygiene & Tropical Medicine Purposes of lecture Introduce concepts of statistical
More informationAvoiding common errors in research reporting:
Avoiding common errors in research reporting: Increasing usability (and potential impact) of your research Iveta Simera Outline Common reporting deficiencies in published research Particularly those limiting
More informationApplication of human epidemiological studies to pesticide risk assessment
Workshop What does the future hold for harmonised human health risk assessment of plant protection products? Application of human epidemiological studies to pesticide risk assessment Antonio F. Hernández,
More informationIntroduction to Experiments
Experimental Methods in the Social Sciences Introduction to Experiments August 5, 2013 Experiments Increasingly Important in the Social Sciences Field experiments in political science as early as 1920s
More informationENDING AIDS, TB AND MALARIA AS EPIDEMICS
ENDING AIDS, TB AND MALARIA AS EPIDEMICS A SMART INVESTMENT In 2000, AIDS, tuberculosis and malaria appeared to be unstoppable. In many countries, AIDS devastated an entire generation, leaving countless
More informationIssues in African Economic Development. Economics 172. University of California, Berkeley. Department of Economics. Professor Ted Miguel
Economics 172 Issues in African Economic Development Professor Ted Miguel Department of Economics University of California, Berkeley Economics 172 Issues in African Economic Development Lecture 11 February
More informationMALARIA & POVERTY IN AFRICA
MALARIA & POVERTY IN AFRICA Edited by Augustin Kwasi Fosu Germano Mwabu University of NAIROBI Library 1111111" 1111111111111111111111111111111 0370077 0 University of Nairobi Press Table of Contents List
More information~Health and Development Initiative~
~Health and Development Initiative~ Global Issues Division International Cooperation Bureau Ministry of Foreign Affairs, Japan March 2007 More than 10 million children
More informationMalaria. Dr. Salim Abdulla, Director Ifakara Health Institute, Dar-es-salaam, Tanzania
Malaria Dr. Salim Abdulla, Director Ifakara Health Institute, Dar-es-salaam, Tanzania Despite 42% reduction since 2000, a child dies every minute in Africa from malaria 207 million malaria cases in 2012,
More informationRole of vaccination and the evaluation of LSD control programmes
Role of vaccination and the evaluation of LSD control programmes Dr Nick Lyons FAO Workshop: LSD prevention and control Tbilisi, Georgia, 11th November 2015 Vaccines and protection Susceptible Infected
More informationStakeholder preferred ways to reduce production diseases in broiler chickens and layer hens
Stakeholder preferred ways to reduce production diseases in broiler chickens and layer hens Philip Jones*, Jarkko Niemi** and Richard Tranter* * Centre for Agricultural Strategy, University of Reading,
More informationBMGF MALARIA STRATEGY TO 2020
BMGF MALARIA STRATEGY TO 2020 Supporting the Drive to Elimination in Mesoamerica & Hispaniola Diana Measham, DrPH, MSc Lead Eliminate Initiative September 25, 2014 The world has three potential future
More informationInvesting for a Malaria-Free World
Investing for a Malaria-Free World Recent years have seen extraordinary advances in the fight against malaria, but the gains are fragile and unevenly distributed. Victory against the malaria parasite would
More informationCatalytic Framework to End AIDS, TB and Eliminate Malaria in Africa by 2030
Catalytic Framework to End AIDS, TB and Eliminate Malaria in Africa by 2030 Introduction The Catalytic Framework to End AIDS, TB and Eliminate Malaria in Africa by 2030 provides an overarching policy framework
More informationThe Cochrane Collaboration s response to the aftermath of the tsunami
The Cochrane Collaboration s response to the aftermath of the tsunami Pisake Lumbiganon, MD, MS Professor in Ob & Gyn Thai Cochrane Network Khon Kaen University Khon Kaen, Thailand 13/05/48 Thai Cochrane
More informationData extraction. Specific interventions included in the review Dressings and topical agents in relation to wound healing.
Systematic reviews of wound care management: (2) dressings and topical agents used in the healing of chronic wounds Bradley M, Cullum N, Nelson E A, Petticrew M, Sheldon T, Torgerson D Authors' objectives
More informationInterpretation of the World Malaria Report Country Profile
Interpretation of the World Malaria Report Country Profile Acknowledgements This presentation was developed to help explain the components of the World Malaria Report Country Profile. The 2017 World Malaria
More informationMonitoring, Evaluation, Accountability, Learning (MEAL) Enabling Environment Finance for. Nutrition
Monitoring, Evaluation, Accountability, Learning (MEAL) 2016 2020 COUNTRY DASHBOARD El Salvador The MEAL Results Framework identifies a wide range of desired results and associated indicators of progress
More informationToyako Framework for Action on Global Health - Report of the G8 Health Experts Group -
Toyako Framework for Action on Global Health - Report of the G8 Health Experts Group - 8 July 2008 This report is the recommendation from the G8 Health Experts Group to the G8 leaders. I Introduction 1.
More informationPreparedness for candidate HCV vaccine trials in people who inject. C Vaccine Initiative*
Preparedness for candidate HCV vaccine trials in people who inject drugs: Challenges and opportunities Li M h b h lf f th UNSW H titi Lisa Maher, on behalf of the UNSW Hepatitis C Vaccine Initiative* Background
More informationUNIÃO AFRICANA ABUJA CALL FOR ACCELERATED ACTION TOWARDS UNIVERSAL ACCESS TO HIV AND AIDS, TUBERCULOSIS AND MALARIA SERVICES IN AFRICA
AFRICAN UNION UNION AFRICAINE UNIÃO AFRICANA ABUJA CALL FOR ACCELERATED ACTION TOWARDS UNIVERSAL ACCESS TO HIV AND AIDS, TUBERCULOSIS AND MALARIA SERVICES IN AFRICA AFRICAN UNION UNION AFRICAINE UNIÃO
More informationTB vaccine progress. Hassan Mahomed. Institute of Infectious Disease and Molecular Medicine, School of Child and Adolescent Health,
TB vaccine progress Hassan Mahomed South African TB Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, School of Child and Adolescent Health, University of Cape Town, South
More informationThe WHO END-TB Strategy
ENDING TB and MDR-TB The WHO END-TB Strategy Dr Mario RAVIGLIONE Director Joint GDI/GLI Partners Forum WHO Geneva, 27 April 2015 This talk will deal with TB Burden Progress, Challenges Way Forward Who
More informationNeed for Chronic Viral Hepatitis Monitoring System
Need for Chronic Viral Hepatitis Monitoring System Harry L.A. Janssen Dept. of Gastroenterology & Hepatology Erasmus University Medical Center Rotterdam The Netherlands Rotterdam November 2008 National
More informationSpecial health needs of women and children
Special health needs of women and children Images used in this presentation are from UNICEF State of the World s Children 2009; and from Wikimedia Commons Julie Byles Women s Health is important to all
More informationGovernment of Canada Federal AIDS Initiative Milestones
HIV in Canada: Trends and Issues for Advancing Prevention, Care, Treatment and Support Through Knowledge Exchange Michael R Smith, Senior Policy Advisor, Programs and Coordination Division, Centre for
More information